Deans' stroke musings: Colchicine reduces hospitalization, death in COVID-19

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, January 25, 2021

Colchicine reduces hospitalization, death in COVID-19

You can ask your doctor why you weren't prescribed colchicine for all its benefits post stroke.

colchicine (8 posts to Dec. 2011)

The latest here:

Colchicine reduces hospitalization, death in COVID-19

Colchicine reduced hospitalization and mortality in patients with COVID-19 by more than 20%, according to topline results of the COLCORONA randomized trial.

According to a press release from the Montreal Heart Institute, the COLCORONA trial indicates colchicine, an anti-inflammatory drug primarily used to treat gout, could prevent cytokine storm and other complications in patients with COVID-19 compared with placebo.

Treating higher-risk patients with colchicine as soon as a confirmed COVID-19 diagnosis reduced risk for developing a severe form of the disease and subsequently lowered the number of hospitalizations, according to the release.

For the contactless, randomized, double-blind, placebo-controlled trial, researchers in Canada, U.S., Europe, South America and South Africa evaluated the efficacy of colchicine in lowering risk for severe complications associated with COVID-19. COLCORONA included approximately 4,488 patients with COVID-19 and at least one other risk factor for COVID-19 complications, who were not hospitalized at the time of enrollment.

In the overall cohort, colchicine reduced death or hospitalization by 21% compared with placebo, a result that “approached statistical significance,” according to the release.

In an analysis of 4,159 patients who had a confirmed COVID-19 diagnosis from a nasopharyngeal PCR test, compared with placebo, colchicine reduced hospitalizations by 25%, the need for mechanical ventilation by 50% and mortality by 44%, and these results were statistically significant, according to the release.

Jean-Claude Tardif

“Our research shows the efficacy of colchicine treatment in preventing the ‘cytokine storm’ phenomenon and reducing the complications associated with COVID-19,” Jean-Claude Tardif, MD, director of the Montreal Heart Institute Research Center and professor of medicine at the Université de Montréal, said in the release. “We are pleased to offer the first oral medication in the world whose use could have a significant impact on public health and potentially prevent COVID-19 complications for millions of patients.”

As Healio previously reported, colchicine has also been shown to reduce CVD risk in high-risk patients from the COLCOT and LoDoCo2 trials.